HUB 101
Alternative Names: HUB-101Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Hubble Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; KCNJ13 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Leber congenital amaurosis